Two Part Study to Assess Comparative Bioavailability, Pharmacokinetics of a Single Dose of ACM-001.1, Two Single Doses of Pindolol (Part1) Followed by Evaluation of Steady State Pharmacokinetics, Pharmacodynamics of ACM-001.1 in HV (Part2)

The aim of this early phase two-part study was to compare the bioavailability (BA) pharmacokinetics (PK) and pharmacodynamics (PD) of racemic pindolol with the benzoate salt of the S-enantiomer of pindolol (ACM-001.1) and provide safety information. A total of 51 healthy male and female subjects were enrolled, and 48 healthy subjects completed the study.
Part 1 consisted of two Groups to compare BA and PK, Group 1 received two treatment sequences of a single dose of ACM-001.1 versus racemic pindolol; Group 2 ran in parallel with Group 1 and assessed the PK of a single dose of racemic pindolol in a single period.
Part 2 consisted of four groups, to evaluate the steady state PK and PD of ACM-001.1 with multiple ascending doses over 4 days.

开始日期2021-11-26

申办/合作机构

Actimed Therapeutics Ltd.

[+1]

NCT01238107

/ Completed临床2期

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects With Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer

A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer

开始日期2011-04-01

申办/合作机构

Akamis Bio Ltd.

[+1]

EUCTR2004-004230-14-IE

/ Not yet recruiting临床2期

A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome.

开始日期2004-12-22

申办/合作机构-

100 项与 Espindolol 相关的临床结果

登录后查看更多信息

100 项与 Espindolol 相关的转化医学

登录后查看更多信息

100 项与 Espindolol 相关的专利（医药）

登录后查看更多信息

369

项与 Espindolol 相关的文献（医药）

2024-09-01·Cancer Medicine

Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis

Review

作者: Honda, Takeshi ; Kazahari, Hiroki ; Ichikawa, Yasuko ; Watanabe, Kiyotaka ; Nagai, Hisashi ; Chen, Hao ; Seki, Nobuhiko ; Tanzawa, Shigeru ; Ishihara, Masashi ; Horita, Nobuyuki ; Ochiai, Ryusuke

Abstract:

Background:

Cancer cachexia affects more than half of all cancer patients, reducing survival rates. Evidence‐based approaches are urgently needed to optimize treatment.

Methods:

A systematic review and network meta‐analysis were conducted to assess the effectiveness and safety of different pharmacotherapies for cancer cachexia. Three databases (PubMed, Cochrane Library, and Web of Science) were searched for the period from January 1, 2000, to March 20, 2024. The netmeta package in R software was used to calculate the pooled effect, employing a random effects model.

Results:

Seven placebo‐controlled randomized trials involving 1421 patients were analyzed. Pairwise analysis showed that body weight increases were 4.6 kg (95% confidence interval [CI] 0.83–8.37 kg) for olanzapine, 3.82 kg (95% CI 0.73–6.91 kg) for espindolol (20 mg), 2.36 kg (95% CI 1.84–2.89 kg) for anamorelin (100 mg), and 1.31 kg (95% CI 0.42–2.19 kg) for anamorelin (50 mg). In terms of safety profiles, olanzapine demonstrated the lowest odds ratio when compared to placebo, at 0.26 (95% CI 0.07–0.94), followed by anamorelin (50 mg) at 0.86 (95% CI 0.30–2.48), and anamorelin (100 mg) at 0.89 (95% CI 0.42–1.88). However, network meta‐analysis could not confirm the superiority of olanzapine over anamorelin in terms of efficacy and safety.

Conclusion:

Both olanzapine and anamorelin are useful in improving body weight in patients with cancer cachexia. Personalization may be helpful for different patients.

2023-06-01·Journal of cachexia, sarcopenia and muscle

Effects of S‐pindolol in mouse pancreatic and lung cancer cachexia models

Article

作者: Ladrón, Natalia Álvarez ; de Lima Junior, Edson Alves ; Springer, Jochen ; Argiles, Josep M ; Marks, Daniel L ; Busquets, Silvia ; Jové, Queralt ; López-Soriano, Francisco Javier

Abstract:

Background:

It is known that S‐pindolol attenuates muscle loss in animal models of cancer cachexia and sarcopenia. In cancer cachexia, it also significantly reduced mortality and improved cardiac function, which is strongly compromised in cachectic animals.

Methods:

Here, we tested 3 mg/kg/day of S‐pindolol in two murine cancer cachexia models: pancreatic cancer cachexia (KPC) and Lewis lung carcinoma (LLC).

Results:

Treatment of mice with 3 mg/kg/day of S‐pindolol in KPC or LLC cancer cachexia models significantly attenuated the loss of body weight, including lean mass and muscle weights, leading to improved grip strength compared with placebo‐treated mice. In the KPC model, treated mice lost less than half of the total weight lost by placebo (−0.9 ± 1.0 vs. −2.2 ± 1.4 g for S‐pindolol and placebo, respectively, P < 0.05) and around a third of the lean mass lost by tumour‐bearing controls (−0.4 ± 1.0 vs. −1.5 ± 1.5 g for S‐pindolol and placebo, respectively, P < 0.05), whereas loss of fat mass was similar. In the LLC model, the gastrocnemius weight was higher in sham (108 ± 16 mg) and S‐pindolol tumour‐bearing (94 ± 15 mg) mice than that in placebo (83 ± 12 mg), whereas the soleus weight was only significantly higher in the S‐pindolol‐treated group (7.9 ± 1.7 mg) than that in placebo (6.5 ± 0.9). Grip strength was significantly improved by S‐pindolol treatment (110.8 ± 16.2 vs. 93.9 ± 17.1 g for S‐pindolol and placebo, respectively). A higher grip strength was observed in all groups; whereas S‐pindolol‐treated mice improved by 32.7 ± 18.5 g, tumour‐bearing mice only show minimal improvements (7.3 ± 19.4 g, P < 0.01).

Conclusions:

S‐pindolol is an important candidate for clinical development in the treatment of cancer cachexia that strongly attenuates loss of body weight and lean body mass. This was also seen in the weight of individual muscles and resulted in higher grip strength.

2023-05-01·European journal of heart failure

The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia.

Article

作者: Doehner, Wolfram ; von Haehling, Stephan ; Anker, Stefan D ; Van Linthout, Sophie ; Palus, Sandra ; Coats, Andrew J S ; Poetsch, Mareike S ; Springer, Jochen

AIMS:

Cachexia, a common manifestation of malignant cancer, is not only associated with weight loss, but also with severe cardiac atrophy and impaired cardiac function. Here, we investigated the effects of ACM-001 (0.3 or 3 mg/kg/day) in comparison to carvedilol (3 or 30 mg/kg/day), metropolol (50 or 100 mg/kg/day), nebivolol (1 or 10 mg/kg/day) and tertatolol (0.5 or 5 mg/kg/day) on cardiac mass and function in a rat cancer cachexia model.

METHODS AND RESULTS:

Young male Wistar Han rats were inoculated i.p. with 10⁸ Yoshida hepatoma AH-130 cells and treated once daily with verum or placebo by gavage. Cardiac function (echocardiography), body weight and body composition (nuclear magnetic resonance scans) were assessed. The hearts of animals were euthanized on day 11 (placebo and 3 mg/kg/day ACM-001) were used for signalling studies. Beta-blockers had no effect on tumour burden. ACM-001 reduced body weight loss (placebo: -34 ± 2.4 g vs. 3 mg/kg/day ACM-001: -14.8 ± 8.4 g, p = 0.033). Lean mass wasting was attenuated (placebo: -16.5 ± 2.34 g vs. 3 mg/kg/day ACM-001: -2.4 ± 6.7 g, p = 0.037), while fat loss was similar (p = 0.4) on day 11. Placebo animals lost left ventricular mass (-101 ± 14 mg), which was prevented only by 3 mg/kg/day ACM-001 (7 ± 25 mg, p < 0.01 vs. placebo). ACM-001 improved the ejection fraction (EF) (ΔEF: placebo: -24.3 ± 2.6 vs. 3 mg/kg/day ACM-001: 0.1 ± 2.9, p < 0.001). Cardiac output was 50% lower in the placebo group (-41 ± 4 ml/min) compared to baseline, while 3 mg/kg/day ACM-001 preserved cardiac output (-5 ± 8 ml/min, p < 0.01). The molecular mechanisms involved inhibition of protein degradation and activation of protein synthesis pathways.

CONCLUSION:

This study shows that 3 mg/kg/day ACM-001 restores the anabolic/catabolic balance in cardiac muscle leading to improved function. Moreover, not all beta-blockers have similar effects.

项与 Espindolol 相关的新闻（医药）

2025-06-26

·GlobeNewswire-Health Care

Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of-concept data expected in second half of 2026 25 June 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces that the first patients have been enrolled in the Company’s Phase 2a muscle optimisation trial PROACT (Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs) investigating the use of S-pindolol benzoate in combination with GLP-1 receptor agonists in the management of obesity and related complications. PROACT is a two-part clinical study programme designed to investigate the safety and the efficacy of S-pindolol benzoate in obese patients. PROACT has two independent primary objectives; firstly, to evaluate the change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst also receiving the GLP-1 agonist semaglutide; and secondly, to evaluate the change in lean and fat mass in patients receiving S-pindolol benzoate after cessation of semaglutide treatment. The main secondary endpoints will be to evaluate the potential role of S-pindolol benzoate on muscle mass, heart and bone composition. Initial data from this proof-of-concept study are expected in the second half of 2026. Fabio Dorigotti, Actimed Chief Medical Officer, commented: “The role of S-pindolol benzoate, with its unique pro-anabolic and anti-catabolic profile, in improving muscle mass has been demonstrated in previous clinical trials in patients with cancer cachexia. We believe the PROACT study will also confirm the benefit of S-pindolol benzoate in preserving muscle mass when used alongside GLP-1 agonists and in optimising and restoring muscle mass after GLP-1 therapy in obese subjects. Our Phase 2a study is designed and powered to give us early proof of concept in this setting, and we look forward to communicating results from the study later next year." Marija Zdravkovic, MD, PhD, FESC, CEO, University Hospital Medical Center Bezanijska kosa, Belgrade, Serbia, added “I am excited to be part of the PROACT study and to contribute to advancing innovative strategies for obesity care. I am particularly delighted that the study will be performed in Serbia and am optimistic that this trial will yield valuable insights and pave the way for a more comprehensive approach to obesity management. Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on advancing muscle health in cancer cachexia, obesity and other muscle wasting disorders. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia and despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. In obese patients receiving current GLP-1RAs for weight loss, muscle preservation is a challenge and new approaches are desirable that preserve a healthy body weight composition. Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an anti-catabolic and pro-anabolic transforming agent (ACTA) targeting multiple pathways that drive cachexia and muscle preservation. Previous studies with S-pindolol have generated promising Phase 2a proof of concept data in cancer cachexia patients and Actimed has conducted a pharmacokinetic and pharmacodynamic (PK/PD) study of S-pindolol benzoate to characterise this new form. In addition, early non-clinical data confirm a potential role for ACM-001.1 in preserving muscle mass when used in combination with GLP-1s for weight loss. Actimed also owns the global rights to S-oxprenolol (ACM-002), which is being developed to treat the muscle wasting and loss of body mass seen in amyotrophic lateral sclerosis (ALS) where it may impact survival. US Orphan Drug Designation has been granted to S-oxprenolol for the treatment of ALS. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for all other indications outside of ALS to US company Faraday Pharmaceuticals. ___________________________ 1 Anker M et al., J. Cachexia, Sarcopenia and Muscle; 2019: 10: 22 – 24 2 Argilés JM et al, Nat Rev Cancer 2014; 14:754-62 3 Bonomi P. et al. The mortality burden of cachexia in patients with non-small-cell lung cancer: A meta-analysis; International Conference of Sarcopenia, Cachexia and Wasting Disorders, June 17 – 18 2023, Stockholm, abstract 2-18, page 139 ⁴ Wolf J et al., PMID 28184974 DOI: 10.1007/s00115-117-0293 The content above comes from the network. if any infringement, please contact us to modify.

孤儿药

2025-06-25

·actimedtherapeutics.com

Actimed Therapeutics Enrols First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of-concept data expected in second half of 2026 London, UK – 25 June 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces that the first patients have been enrolled in the Company’s Phase 2a muscle optimisation trial PROACT (Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs) investigating the use of S-pindolol benzoate in combination with GLP-1 receptor agonists in the management of obesity and related complications. PROACT is a two-part clinical study programme designed to investigate the safety and the efficacy of S-pindolol benzoate in obese patients. PROACT has two independent primary objectives; firstly, to evaluate the change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst also receiving the GLP-1 agonist semaglutide; and secondly, to evaluate the change in lean and fat mass in patients receiving S-pindolol benzoate after cessation of semaglutide treatment. The main secondary endpoints will be to evaluate the potential role of S-pindolol benzoate on muscle mass, heart and bone composition. Initial data from this proof-of-concept study are expected in the second half of 2026. Fabio Dorigotti, Actimed Chief Medical Officer, commented: “The role of S-pindolol benzoate, with its unique pro-anabolic and anti-catabolic profile, in improving muscle mass has been demonstrated in previous clinical trials in patients with cancer cachexia. We believe the PROACT study will also confirm the benefit of S-pindolol benzoate in preserving muscle mass when used alongside GLP-1 agonists and in optimising and restoring muscle mass after GLP-1 therapy in obese subjects. Our Phase 2a study is designed and powered to give us early proof of concept in this setting, and we look forward to communicating results from the study later next year." Marija Zdravkovic, MD, PhD, FESC, CEO, University Hospital Medical Center Bezanijska kosa, Belgrade, Serbia, added “I am excited to be part of the PROACT study and to contribute to advancing innovative strategies for obesity care. I am particularly delighted that the study will be performed in Serbia and am optimistic that this trial will yield valuable insights and pave the way for a more comprehensive approach to obesity management." *** About Actimed Therapeutics Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on advancing muscle health in cancer cachexia, obesity and other muscle wasting disorders. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia1 and despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. In obese patients receiving current GLP-1RAs for weight loss, muscle preservation is a challenge and new approaches are desirable that preserve a healthy body weight composition. Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an anti-catabolic and pro-anabolic transforming agent (ACTA) targeting multiple pathways that drive cachexia and muscle preservation. Previous studies with S-pindolol have generated promising Phase 2a proof of concept data in cancer cachexia patients and Actimed has conducted a pharmacokinetic and pharmacodynamic (PK/PD) study of S-pindolol benzoate to characterise this new form. In addition, early non-clinical data confirm a potential role for ACM-001.1 in preserving muscle mass when used in combination with GLP-1s for weight loss. Actimed also owns the global rights to its second asset, S-oxprenolol (ACM-002), which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival2. US Orphan Drug Designation has been granted to S-oxprenolol for the treatment of ALS. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for all other indications outside of ALS to US company Faraday Pharmaceuticals. FOR MORE INFORMATION Actimed Therapeutics MEDiSTRAVA Frazer Hall, Erica Hollingsworth Tel: +44 (0)203 928 6900 Email: actimed@medistrava.com 1 Anker M et al., J. Cachexia, Sarcopenia and Muscle; 2019: 10: 22 – 24 2Wolf J et al., PMID 28184974 DOI: 10.1007/s00115-117-0293

临床2期孤儿药

2025-05-20

·actimedtherapeutics.com

Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists

Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass, cardiac protection and bone mineral density in obese subjects. London, UK – 20th May 2025. Actimed Therapeutics, a UK-based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces the commencement of a new development programme investigating the potential benefits of using S-pindolol benzoate (ACM-001.1) during and post-GLP-1 receptor agonist (GLP-1RA) therapy in the management of obesity and related metabolic conditions. This new initiative comprises a two-part programme: Approved GLP-1RAs have shown significant efficacy in reducing fat mass, but this is frequently accompanied by an unwanted reduction in lean body mass (LBM), including skeletal muscle1,2. The loss of LBM is of particular concern in older or frail individuals or patients with co-morbidities as it could lead to impaired function and increased morbidity. Moreover, cessation of GLP-1RA therapy can result in a rebound in body weight in favour of fat mass and at the expense of LBM, resulting in a less favourable muscle to fat ratio3. S-pindolol benzoate is an agent with pro-anabolic and anti-catabolic properties, and in both nonclinical and clinical studies of cancer cachexia, has demonstrated the ability to improve muscle mass. This suggests a potential utility in obese patients during or following GLP-1RA therapy. Moreover, through its ß1-adrenoreceptor blocking effects, S-pindolol has the potential to enhance cardiovascular benefits associated with GLP-1RAs. Robin Bhattacherjee, Actimed CEO, commented: “We are extremely excited to announce the launch of this new development programme, PROACT, which is a natural extension of our mission to address serious muscle wasting conditions. We believe the use of S-pindolol benzoate in patients receving or who have received GLP-1RAs represents a highly promising therapeutic strategy. This programme underscores our continued commitment to advancing innovative therapies that can significantly improve outcomes for patients at risk of muscle wasting.” Dr David Ebsworth, Actimed Executive Chairman, commented: "This programme represents a thoughtful and strategic expansion of our development pipeline. By leveraging the unique properties of S-pindolol benzoate in combination with GLP-1RAs, we are addressing a significant unmet need while remaining firmly aligned with our strategic focus on muscle wasting disorders. We would like to thank our lead investors for their continued support, which enables us to pursue opportunities like this that are both scientifically compelling and commercially promising." The company remains fully committed to the ongoing development of S-pindolol benzoate for cancer cachexia and is continuing efforts to raise funds for the IMPACT clinical programme. *** About Actimed Therapeutics Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia1 and it is estimated that cachexia is responsible for up to 20% of all cancer deaths1. A recent meta-analysis demonstrated that cachexia was associated with an 82% higher relative risk of mortality in patients with NSCLC versus no cachexia1. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an anti-catabolic and pro-anabolic transforming agent (ACTA) targeting multiple pathways that drive cancer cachexia. Previous studies with S-pindolol have generated promising Phase 2a proof of concept data in cachexia patients and Actimed has conducted a pharmacokinetic and pharmacodynamic (PK/PD) study of S-pindolol benzoate to characterise this new form. ACM-001.1 has achieved Investigational New Drug (IND) status from FDA. Actimed also owns the global rights to its second asset, S-oxprenolol (ACM-002), which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival4. Actimed was granted US Orphan Drug Designation to S-oxprenolol for the treatment of ALS in 2024. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for cancer cachexia and any other indications outside of ALS to US company Faraday Pharmaceuticals. FOR MORE INFORMATION Actimed Therapeutics MEDiSTRAVA Frazer Hall, Erica Hollingsworth Tel: +44 (0)203 928 6900 Email: actimed@medistrava.com 1 Wilding JPH, Batterham RL, Calanna S, et al. (2021) N Engl J Med.;384 (11):989–1002. doi: 10.1056/NEJMoa2032183 2McCrimmon RJ, Catarig A-M, Frias JP, et al. (2020) Diabetologia.;63:473–485. doi: 10.1007/ s00125-019-05065-8 3Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564. doi:10.1111/dom.14725 4Anker M et al., J. Cachexia, Sarcopenia and Muscle; 2019: 10: 22 – 24 5Argilés JM et al, Nat Rev Cancer 2014; 14:754-62 6Bonomi P. et al. The mortality burden of cachexia in patients with non-small-cell lung cancer: A meta-analysis; International Conference of Sarcopenia, Cachexia and Wasting Disorders, June 17 – 18 2023, Stockholm, abstract 2-18, page 139 7Wolf J et al., PMID 28184974 DOI: 10.1007/s00115-117-0293

临床2期孤儿药临床结果

100 项与 Espindolol 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床2期	塞尔维亚	Actimed Therapeutics Ltd.	2025-06-25
结直肠癌	临床2期	德国	Akamis Bio Ltd.	2011-04-01
结直肠癌	临床2期	印度	Akamis Bio Ltd.	2011-04-01
结直肠癌	临床2期	马来西亚	Akamis Bio Ltd.	2011-04-01
转移性非小细胞肺癌	临床2期	德国	Akamis Bio Ltd.	2011-04-01
转移性非小细胞肺癌	临床2期	印度	Akamis Bio Ltd.	2011-04-01
转移性非小细胞肺癌	临床2期	马来西亚	Akamis Bio Ltd.	2011-04-01
恶病质	临床2期	德国	Akamis Bio Ltd.	2011-04-01
恶病质	临床2期	印度	Akamis Bio Ltd.	2011-04-01
恶病质	临床2期	马来西亚	Akamis Bio Ltd.	2011-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06028321 (Pubmed) 人工标引	临床1期	-	51	ACM-001.1 (Parts 1)	憲顧願製願憲餘範構齋(鑰顧顧膚艱願製構憲衊) = 醖憲願觸構觸範襯醖鬱鹽壓衊壓鏇築鹽鹹夢鬱 (遞願遞蓋衊餘蓋鏇壓廠 ) 更多	积极	2024-12-12
				ACM-001.1 (Parts 2)	憲顧願製願憲餘範構齋(鑰顧顧膚艱願製構憲衊) = 蓋鏇繭鏇鹽製廠壓廠膚鹽壓衊壓鏇築鹽鹹夢鬱 (遞願遞蓋衊餘蓋鏇壓廠 ) 更多